Prospective, multicenter Swiss registry study evaluating the performance of 177Lu-ITG-PSMA-1 (177Lu-PSMA-I\&T) as RLT in mCRPC.
Primary endpoint: Safety-
* frequency and severity of adverse events (measured according to CTCAE 5.0). Secondary endpoints: Efficacy
* biochemical response: best PSA response, PSA50 (\>50% decrease from baseline PSA level) and PSA response at 12 weeks
* imaging response: Objective response rate evaluated on follow-up morphological imaging CT/MRI and/or on molecular imaging PSMA PET/CT
* quality of life: evaluated with standardized questionnaires
